share_log

Panbela Therapeutics | 424B3: Prospectus

Panbela Therapeutics | 424B3: Prospectus

Panbela Therapeutics | 424B3：募資說明書
美股SEC公告 ·  07/31 12:37

Moomoo AI 已提取核心訊息

Panbela Therapeutics has filed a prospectus supplement on July 30, 2024, to update information related to the resale of 255,600 shares of common stock by selling securityholders, as part of its registration statement on Form S-1. The supplement follows a current report on Form 8-K filed on the same date, detailing a new loan agreement entered into on July 24, 2024, between Panbela Therapeutics and its subsidiary, Cancer Prevention Pharmaceuticals, Inc., with USWM, LLC. The loan agreement provides a term loan of $1.5 million with specific interest and premium terms, maturing on the earliest of a qualifying financing or transaction closing, or December 31, 2024. The proceeds are designated for payment of fees and expenses to a contract research organization, working capital purposes, and related fees or expenses. The company has also entered into a security agreement granting USWM, LLC a first priority security interest in all rights, title, and interest in the Asset Purchase Agreement to secure the obligations under the loan.
Panbela Therapeutics has filed a prospectus supplement on July 30, 2024, to update information related to the resale of 255,600 shares of common stock by selling securityholders, as part of its registration statement on Form S-1. The supplement follows a current report on Form 8-K filed on the same date, detailing a new loan agreement entered into on July 24, 2024, between Panbela Therapeutics and its subsidiary, Cancer Prevention Pharmaceuticals, Inc., with USWM, LLC. The loan agreement provides a term loan of $1.5 million with specific interest and premium terms, maturing on the earliest of a qualifying financing or transaction closing, or December 31, 2024. The proceeds are designated for payment of fees and expenses to a contract research organization, working capital purposes, and related fees or expenses. The company has also entered into a security agreement granting USWM, LLC a first priority security interest in all rights, title, and interest in the Asset Purchase Agreement to secure the obligations under the loan.
Panbela Therapeutics已於2024年7月30日提交了招股說明書，以更新與賣出安防-半導體股票的255,600名常股持有人有關的信息，作爲其S-1表格的註冊聲明的一部分。該補充說明書遵循同一天提交的8-K表格的現有報告，詳細說明Panbela Therapeutics及其子公司Cancer Prevention Pharmaceuticals，Inc.與USWm，LLC於2024年7月24日簽訂的新貸款協議。該貸款協議提供了一項150萬美元的定期貸款，具有特定的利息和溢價條款，在符合資格的融資或交易結算或2024年12月31日到期。所得款項被指定用於支付合同研究組織的費用和支出、營運資金目的、以及相關費用或支出。公司還簽署了一份安全協議，將資產購買協議的所有權、標題和權益賦予USWm，LLC，以擔保貸款的義務。
Panbela Therapeutics已於2024年7月30日提交了招股說明書，以更新與賣出安防-半導體股票的255,600名常股持有人有關的信息，作爲其S-1表格的註冊聲明的一部分。該補充說明書遵循同一天提交的8-K表格的現有報告，詳細說明Panbela Therapeutics及其子公司Cancer Prevention Pharmaceuticals，Inc.與USWm，LLC於2024年7月24日簽訂的新貸款協議。該貸款協議提供了一項150萬美元的定期貸款，具有特定的利息和溢價條款，在符合資格的融資或交易結算或2024年12月31日到期。所得款項被指定用於支付合同研究組織的費用和支出、營運資金目的、以及相關費用或支出。公司還簽署了一份安全協議，將資產購買協議的所有權、標題和權益賦予USWm，LLC，以擔保貸款的義務。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間